Surgery plus chemo versus chemo alone for ovarian cancer relapse
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your ovarian/peritoneal/fallopian tube cancer has come back (first- or second-line relapse).
- You previously had at least 4 cycles of platinum-based chemotherapy, and the relapse happened more than 6 months later.
- You were on a PARP inhibitor (“PARPi”) maintenance treatment for more than 6 months before the relapse.
- Your initial surgery was able to remove all visible disease (R0 “ideal debulking”).
- Your scans show a limited, isolated recurrence (up to 5 spots) and very little/no fluid in the belly (ascites < 500 mL).
- You’re well enough for surgery and treatment (performance status 0–1) and your blood, kidney, and liver tests are within required ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
This trial tests if a second surgery to remove tumors, followed by heated chemotherapy in the abdomen, helps people with ovarian, fallopian tube, or peritoneal cancer whose cancer has returned while taking PARP inhibitor drugs.
This trial tests whether a second surgery to remove all visible cancer can help people with ovarian cancer that came back within 6 months of finishing platinum chemotherapy. The goal is to see if this surgery improves outcomes compared with standard care.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
This trial compares two ways of treating advanced ovarian cancer: having surgery first, or having chemotherapy first followed by surgery. The goal is to see which approach improves outcomes for patients.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
Hear when a new Relapsed Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.